ニューキノロン使用指針

書誌事項

タイトル別名
  • Guideline for the Treatment of Leprosy by New Quinolones

この論文をさがす

抄録

Ofloxacin(OFLX) is often applied today as a substitution drug of MDT for drug resistance to dapsone, rifampicin or clofazimine. However, OFLX resistance is also becoming a great concern. Low and/or irregular administration are considered to be the major causes of OFLX resistance. OFLX should be used as a combined therapy, and minimal daily dose of 400mg of OFLX or 200 ?? 300mg of levofloxacin is required. Quinolone resistance should be considered when no improvement of clinical and/or bacterial index is observed after the treatment for 6 months. In such cases, resistance gene detection is necessary.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (6)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ